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Major depressive disorder (MDD) poses one of the highest disease burdens worldwide.
Yet, current treatments targeting serotonergic and noradrenaline reuptake systems are
insufficient to provide long-term relief from depressive symptoms in most patients,
indicating the need for new treatment targets. Having the ability to influence
behavior similar to depressive symptoms, as well as communicate with neuronal and
neuroendocrine systems, the innate immune system is a strong candidate for MDD
treatments. Given the complex nature of immune signaling, the main question becomes:
What is the role of the innate immune system in MDD? The current review presents
evidence that toll-like receptor 4 (TLR4), via driving both peripheral and central immune
responses, can interact with serotonergic neurotransmission and cause neuroendocrine
disturbances, thus integrating with widely observed hallmarks of MDD. Additionally,
through describing the multi-directional communication between immune, neural and
endocrine systems in stress, TLR4—related mechanisms can mediate stress-induced
adaptations, which are necessary for the development of MDD. Therefore, apart from
exogenous pathogenic mechanisms, TLR4 is involved in immune changes as a result of
endogenous stress signals, playing an integral part in the pathophysiology, and could be a
potential target for pharmacological treatments to improve current interventions for MDD.
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INTRODUCTION
Major depressive disorder (MDD) represents a combination of
disturbances tomood, cognition, sleep and appetite, which causes
impairment to individual functioning lasting a minimum of 2
weeks (American Psychiatric Association, 2013). MDD consis-
tently ranks within the top 4 highest “years lived with disability”
(Vos et al., 2012), and accounts for 7.4% of total disability-
adjusted life years worldwide (Whiteford et al., 2013). In addi-
tion, depressive disorders have an estimated 93.5% comorbidity
with other diseases, most commonly with chronic pain, anxiety,
bipolar disorder, post-traumatic stress disorder, diabetes and neu-
rological disorders (Gadermann et al., 2012). Major depression
thus bears one of the highest disease burdens, with matching eco-
nomic and societal costs. Yet, current pharmacological treatments
using serotonin and noradrenaline reuptake inhibitors (SSRI and
SNRI, respectively) are inefficient, requiring to treat 7 patients in
order to gain one positive outcome (Arroll et al., 2009). This sug-
gests that alterations to the serotonergic pathway are only partly
responsible for MDD, and other mechanisms must be involved.
Thus, it is sensible to study other systems, in order to improve
current treatments for MDD.
Ever since early observations of increased immune markers in
psychiatric patients, the immune system has become increasingly
associated with various psychosomatic illnesses (Solomon et al.,
1969). In the case of MDD, patients exhibit increased circulat-
ing peripheral cytokines, which are immune signaling molecules
that can be pro or anti-inflammatory (Anisman and Hayley,
2012; Lichtblau et al., 2013). Additionally, a decrease in depressive
symptoms is coupled with a normalization of immune signaling
levels (Gazal et al., 2013), suggesting that there may be immune
involvement in MDD.
NEUROINFLAMMATORY EVENTS: NEUROINFLAMMATION
AND NEUROKINE SIGNALING IN MDD
Although immune signaling in the brain is comprised of sig-
nals from resident glial cells, peripheral to central immune
communications and migration of peripheral cells into central
compartments, it is important to note the phenotypic differ-
ences between different neuroinflammatory diseases. The term
“Neuroinflammation” is commonly used to encompass increased
immune activation in the CNS. However, the central nervous sys-
tem (CNS) can take on different inflammatory states, and there
is a distinction between the magnitude of immune responses
in the CNS by varied causes. For example, neurodegenerative
disorders including Alzheimer’s and Parkinson’s disease are char-
acterized by widespread immune signaling in the CNS, oxidative
stress, and increased immune trafficking into the brain, resulting
in systemic inflammation accompanied with progressive damage
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(Heneka et al., 2014). On the other hand, acute and sub-maximal
immune challenges such as that triggered by opioid exposure can
also cause increased central immune signaling, but the resulting
inflammatory response is of a much lower magnitude (Stevens
et al., 2013). This sub-inflammatory state is attributed to the
direct actions of opioids on CNS expressed toll-like receptor 4
(TLR4), since opioids readily cross the BBB, rather than the indi-
rect peripheral to central immune response following bacterial
infections (Hutchinson and Watkins, 2014; Jacobsen et al., 2014).
Classically, inflammation involves swelling, heat, and pain,
coupled with a coordinated infiltration of various immune cells
into the affected area. In many neurological conditions, this large-
scale damage is not seen unless in terminal stages, or in cases
of major BBB compromise. Thus, the use of “neuroinflamma-
tion” to refer to central immune activity can become confusing,
and a clear distinction between high magnitude and submaximal
immune states is required.
Neurokines refer to neurally active cytokines (Nathanson,
2012), which can be upregulated as a result of peripheral infec-
tions or innate immune activation without the infectious agent
crossing the BBB (McCusker and Kelley, 2013). An important
differentiation between increased neurokine signaling and neu-
roinflammation is the reversibility of the effects. Central cytokine
increase resulting from low-grade infections, exercise and stress
result in reversible neuronal changes (McCusker and Kelley,
2013). These neuronal changes include the upregulation of AMPA
and NMDA receptors, as well as decreased expression of GABA
receptors on neurons by cytokines IL-1β and TNF-α, causing
reversible increased excitation (see Viviani et al., 2014 for a
review). We thus propose the use of the terms “increased neu-
rokine signaling” or “increased central immune signaling” to
apply to these sub-inflammatory states, and only when there is
large-scale damage as a result of immune cell derived neurotoxi-
city and inflammation should the term “neuroinflammation” be
applied in order to reduce confusion within the literature.
In regards to MDD, current evidence indicates a milder
immune signaling phenotype more akin to increased neurokine
signaling, rather than neuroinflammation. Compared with the
continued accumulated loss of function observed in neurode-
generative disorders such as Alzheimer’s and Parkinson’s disease,
MDD has periods of active disease characterized by depressive
episodes followed by remission. During remission, peripheral
blood expression of TNF superfamily 12–13 mRNA is lower
than in active disease (Otsuki et al., 2010). This indicates that
the immune signaling is influenced by the state of the dis-
order, but critically, the degree of immune signaling required
for the presentation of a disease symptom may be significantly
higher than that needed for MDD to be observed, as illus-
trated by the development of depressive-like behavior prior to
the development of significant demyelination in experimental
autoimmune encephalitis (Acharjee et al., 2013). Furthermore,
structural changes in hippocampal volume measured using MRI
appear reversible in patients with MDD (Frodl et al., 2004).
Antidepressants (Horikawa et al., 2010; Alboni et al., 2013;
Obuchowicz et al., 2014) and cognitive-behavioral therapy (Gazal
et al., 2013) are also able to reduce cytokine expression in depres-
sive disorders. Taken together, there is strong evidence for the
reversibility of inflammatory markers that closely relates to the
state of depressive symptoms. Along with the bi-directional neu-
roimmune connection, this reversibility and liability of the con-
dition suggests that targeting the central immune system could be
a promising treatment option for MDD.
THE ROLE OF TOLL-LIKE RECEPTOR 4 IN MDD
Recently, TLR4 has come to the forefront of research linking
neuroimmune signaling and MDD, through driving immune to
brain communication. TLR4 is an innate immune pattern recog-
nition receptor, which is part of the Interleukin-1 Receptor/Toll-
Like Receptor Superfamily containing a toll-like/IL-1 Receptor
(TIR) domain and Leucine-rich repeat motif in the extracellular
domain. TLR4 recognizes endogenous danger associated molec-
ular patterns (DAMPs) including heat shock proteins (HSP)
and high mobility group box 1 (HMGB1), exogenous pathogen
associated molecular patterns (PAMPs) such as lipopolysaccha-
ride (LPS), as well as microbiome/microbe associated molecu-
lar patterns (MAMPs) (Akira and Takeda, 2004). Unlike other
toll-like receptors, activation of TLR4 triggers pro-inflammatory
transcription via 2 adaptor proteins, Myeloid differentiation pri-
mary response 88 (MyD88) and TIR domain-containing adapter
inducing IFN-β (TRIF), which induces transcription factors
NF-κB, AP-1, and IRF3 (Xu et al., 2000; Watters et al., 2007).
Activation of these transcription factors causes the production
of pro-inflammatory cytokines including IL-1β, TNF-α, IL-6,
and CXCL10, along with an upregulation of proteins includ-
ing cyclooxygenase 2 (COX-2), resulting in pro-inflammatory
signaling (Akira and Takeda, 2004).
In the CNS, TLR4 is predominantly expressed on microglia,
and is also to a lesser extent expressed on neurons (Zhao et al.,
2014). Through modulation of neuroimmune activity, TLR4 is
implicated in various neuropathological conditions that afflict the
CNS, including neuropathic pain (Lewis et al., 2012) and neu-
rodegenerative diseases (Heneka et al., 2014). Increasingly, these
disorders are recognized as existing on a spectrum from altered
neuroimmune signaling (e.g., neuropathic pain) through to gross
neuroinflammation (e.g., Neurodegenerative diseases).
MDD, being increasingly classified as a neuroimmune disor-
der, may also have TLR4 involvement (Gárate et al., 2011; Hines
et al., 2013). Recent evidence has found that peripheral blood
mononuclear cells (PBMC) of patients with MDD express higher
levels of TLR4 (Kéri et al., 2014). Importantly, the authors showed
that this heightened expression was reduced following treat-
ment, and paralleled improvement in depressive symptoms. This
responsiveness toward depressive states indicates that TLR4 activ-
ity could directly be involved in the pathophysiology of MDD.
Given the involvement of the immune system in numerous
neurological disorders, it is now accepted that the CNS is not an
immune privileged organ that exists in isolation of the immune
system. The CNS can no longer be thought of as resistant to
immune signals, or protected from immune damage (Ransohoff
and Brown, 2012). Rather than separate entities, immune, neu-
ronal and endocrine systems appear to be in constant bidirec-
tional communication and a dysregulation of these systems can
result in pathological states within the CNS (see Kelley and
McCusker, 2014 for review). The current review thus posits
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that TLR4, being central to the immune to brain, and immune
to neuroendocrine communication, underlies the neuroimmune
signaling events observed in the pathophysiology of stress-related
disorders including MDD, across systemic and cellular levels.
TLR4 ACTIVITY CAN INFLUENCE BEHAVIOR AND MDD
Using LPS as an agonist, peripheral TLR4 activation is sufficient
to cause changes in motivational state and can trigger sickness
behavior (Hines et al., 2013). Sickness behavior is characterized
by increased anhedonia, lethargy, loss of locomotion and anorexia
following immune challenges (Dantzer and Kelley, 2007). Once
thought to stem from altered energy balance, it is clear that these
immune signaling initiated behavioral adaptations are driven by
specific cytokine-dependent signaling cascades (Dantzer, 2004).
Thus, an immune stimulus can drive complex higher order
behavioral adaptations, providing direct evidence for the link
between the immune system and symptoms of depression.
Although the idea of sickness behavior may appear surprising
since pathogens themselves are imperceptible by our classic sen-
sory organs, it makes sense that the body needs to know when it
encounters pathogens in order to make behavioral adjustments.
Through reduction in locomotion, sickness behavior can pro-
mote recovery from the immune challenges. Sickness behavior
can therefore be considered as adaptive since it promotes home-
ostasis within the conditions of the stressor (Dantzer and Kelley,
2007).
The effect of peripheral immune activation on behavior is
thought to bemediated by threemainmechanisms: (1) peripheral
release of pro-inflammatory cytokines can cross the blood brain
barrier (BBB) via “leaky” subventricular organs, thus directly
increasing neurokine signaling, (2) These activated immune cells
can also cross the BBB directly to cause neuroimmune signaling,
and (3) peripheral cytokines can also stimulate afferent pathways
such as the vagus nerve, causing behavioral changes via neural
mechanisms (see McCusker and Kelley, 2013 for review). Besides
these mechanisms, emerging evidence have demonstrated that
monocytes can adhere and roll along the cerebral vasculature, and
can cause increased central immune signaling without crossing
the BBB, and this is associated with increases in inducible Nitric
Oxide Syntase (D’Mello et al., 2013). The authors further showed
that inhibiting this mechanism could improve sickness behavior
as a result of peripheral inflammation, thus suggesting another
mode of peripheral to central communication with behavioral
implications.
Importantly, the trigger for behavioral changes need not orig-
inate from pathogenic mechanisms, since cytokine administra-
tion is sufficient to elicit sickness behavior similar to bacterial
stimulation (Tazi et al., 1988; Dantzer, 2004). This means that
other potential sources of immune activation, including endoge-
nous danger signals, or neurogenic activation could trigger this
response.
Strong parallels can be drawn between sickness behavior and
depressive behavior, namely reduced locomotion, anhedonia, and
dysregulated sleep and food intake (McCusker and Kelley, 2013).
Since MDD can be chronic and recurring, the question arises
whether patients with MDD are just displaying chronic dysreg-
ulation in inflammation or immune signaling? Indeed, patients
suffering from MDD display heightened circulating cytokine
levels, indicative of increased immune signaling (Anisman and
Hayley, 2012; Lichtblau et al., 2013). Furthermore, there is some
evidence showing that celecoxib, an NSAID that inhibits COX-2,
can improve depression scores as well as increase remission
rates in patients receiving anti-depressants (Faridhosseini et al.,
2014; Na et al., 2014). In rodent models, NSAID administration
can improve depressive-like behavior, measured using the forced
swim test and tail suspension tests (Maciel et al., 2013; Guan
et al., 2014). Notably however, these studies indicate that the anti-
depressive effect of NSAID requires a higher dose in order to
achieve comparable results to SSRIs, and are more effective in
immune stressor induced depressive-like behavior. Additionally,
there is some debate about the efficacy of these treatments since
NSAIDs can also reduce efficacy of SSRI treatment when given
in conjunction, in both animals and patients (Warner-Schmidt
et al., 2011). MDD thus appears to have an immune component,
but the exact mechanisms behind this interaction require more
investigation.
CELL MEDIATED MECHANISMS OF CENTRAL IMMUNE SIGNALING
EVENTS ASSOCIATED WITH MDD
It has been confirmed that both peripheral and central adminis-
tration of LPS can induce sickness behavior, showing that both
peripheral and central immune signaling are involved in perpet-
uating this behavioral change (Huang et al., 2008; Hines et al.,
2013). This TLR4 mediated Innate immune signaling in the CNS
is mainly undertaken by 2 cell populations, the resident glial cells,
and infiltrating peripheral immune cells.
Glial cells, consisting of oligodendrocytes, astrocytes and
microglia, vastly outnumber neurons by an estimated 10–50-
fold (Temburni and Jacob, 2001; Banati, 2003). These cells were
previously regarded as inert support cells that do not directly
influence neurotransmission. However, there is increasing evi-
dence that glial cells are integral to both physiological functions
and pathophysiological states in the CNS.
Astrocytes
Astrocytes are the most abundant cell type in the CNS, providing
structural and trophic support to neurons. They have star-shaped
morphology, with processes that can be in contact with up to
100,000 neurons (Halassa et al., 2007). Although astrocytes are
not capable of producing action potentials, neurotransmitter
binding to receptors present on astrocytes can induce Ca2+waves
(Sharma and Vijayaraghavan, 2001; Schipke et al., 2011). In addi-
tion to forming close appositions with synapses, astrocytes can
influence the chemical environment through secretion of various
compounds such as ATP, adenosine and acetylcholine, a process
known as gliotransmission. Astrocytes can therefore influence
neurotransmission on a synaptic level and could play a role in
aggregating neural responses. Collectively, astrocyte involvement
with synaptic activity is termed the tripartite synapse (Araque
et al., 2014).
Across the CNS, astrocytes display different phenotypes and
can adopt different states (Sun and Jakobs, 2012). Activated
astrocytes display less branching morphological characteristics,
and this is associated with glial fribrillary acid protein (GFAP)
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upregulation (Pekny and Nilsson, 2005). Activated in injury,
astrocytes can be both protective by releasing factors facilitat-
ing recovery (Gimsa et al., 2013), and disruptive to neuronal
functioning via inhibiting axon growth through formation of
glial scars after extended activation (Smith-Thomas et al., 1994;
Yuan and He, 2013). Moreover, radial glia located at the sub-
ventricular zones also express GFAP, but act as precursor cells
capable of differentiating into neurons and astrocytes, which can
migrate to several areas including the cortex, displaying abil-
ity for adult neurogenesis and cell renewal (Sundholm-Peters
et al., 2005). The role of astrocytes is therefore varied and impor-
tant to normal physiology, but astrocytes can also participate
in both neuroimmune signaling and neuroinflammatory disease
progression.
In MDD, astrocytes may be involved in the progression of the
disease through participating in the reuptake of serotonin. In the
presence of TNF-α, serotonin transporters expressed on astro-
cytes increase reuptake of serotonin in a dose-dependent manner,
and this effect is attenuated by administration of SSRIs (Malynn
et al., 2013). Interestingly, SSRI are also able to influence astro-
cytic Ca2+ waves in a similar way to serotonin administration
(Schipke et al., 2011). Although unclear whether astrocytes are
an integral target for anti-depressant treatment, it appears that
astrocytes can play a role in serotonin neurotransmission, and
therefore be involved in the pathophysiology of MDD.
Microglia
Microglia are the resident immunocompetent cells in the CNS,
and play an active role in neuroinflammatory actions by release
of cytokines, chemokines phagocytosis and removal of debris,
directly modulating neuroimmune activity. Microglia are thus the
main cell type investigated in neuroimmune signaling events and
neuroinflammatory/neurodegenerative conditions. Being impli-
cated in synaptic pruning during CNS development, microglia
not only perpetuate damage, but also are integral for normal
functioning (Schwartz et al., 2013). Microglia too have differ-
ent activation states, commonly referred to as M1 and M2,
the pro and anti-inflammatory phenotypes, respectively (Olah
et al., 2011). When activated to an M1 phenotype, microglia
display a more ameboid morphology, and secrete cytokines
and chemokines to signal for other immune cells. Microglia
can also function as antigen presenting cells through MHC-II
expression, therefore possessing the ability to trigger the adap-
tive immune responses within the CNS (Harms et al., 2013).
Expressing pattern recognition receptors such as TLR4, microglia
are responsive to DAMPs, MAMPs, and PAMPs. Moreover, TLR4
activation can shift microglia toward a M1 phenotype, induc-
ing pro-inflammatory responses in the CNS (Ajmone-Cat et al.,
2013).
Besides functioning as an antigen-presenting cell, microglia
can influence neuronal functions through expression of gluta-
mate transporters (Persson et al., 2005), but to a lesser extent
as compared to astrocytes (Beschorner et al., 2007). In addi-
tion, microglia in the “resting” state actively survey the sur-
rounding area for chemical changes, and can rapidly respond
to stimuli (Nimmerjahn et al., 2005). Thus, even during an
immunologically dormant state, microglia are able to influence
neurotransmission and can rapidly respond to danger signals.
Aiding this responsiveness are the toll-like receptors, which can
recognize multiple stimuli and modulate the activation states of
microglia.
Microglia, through TLR4-dependent signaling (Hines et al.,
2013), and production of cytokines (Henry et al., 2009; Dobos
et al., 2012), are regarded as mediators of central immune signal-
ing in animal models of sickness behavior. In addition, changes
in microglial reactivity states are also associated with the induc-
tion of stress-induced depressive like behavior (Pan et al., 2014).
In a recent study, minocycline, an antibiotic that has also shown
the ability to suppress central immune signaling by acting on
microglia, can prevent the development of depressive-like behav-
ior, tested using sucrose preference and social exploration (Kreisel
et al., 2014). This reduction of depressive-like behavior was found
in conjunction with changes to microglia morphology and pro-
liferation. On the other hand, the study illustrated that simply
inhibiting microglia chronically would not be a viable treat-
ment option, since microglial activation states change from an
initial proliferative state to later decline from acute to chronic
models, and central immune suppression exacerbates depressive-
like behavior in a chronic model. Instead, the authors proposed
that depression is related to either an over or under activation
of microglia, and treatments should strive toward a balance in
activation states. Taken together, microglia appear important in
central immune signaling and immune to brain communication
in MDD, but this relationship is not is not uni-directional, and
appears to be time-dependent.
Peripheral immune cells and their actions on the CNS
Although the CNS is protected from many peripheral factors by
the BBB, peripheral immune cells have been found to infiltrate
and drive inflammation within the CNS (Schweingruber et al.,
2014; Vogel et al., 2014). Perivascular macrophages and circu-
lating monocytes can cross the BBB into the CNS through the
expression of adhesion molecules such as ICAM and VCAM on
the endothelium of blood vessels surrounding the CNS (Wong
et al., 2007). Additionally, peripheral leukocytes can also roll and
adhere to the cerebral vasculature, and cause increased central
immune signaling without entering the CNS, thus communicat-
ing across the BBB (D’Mello et al., 2013). Glial cells themselves
can also release chemokines such as CCL2, which can trigger
peripheral immune cell extravasation into CNS tissue (Williams
et al., 2013; Shieh et al., 2014). Thus, the central immune system
can actively signal for peripheral immune cells to cross the BBB.
Contrary to other models of neuroinflamma-
tory/neurodegenerative disorders Wohleb et al. (2014) have
recently shown that peripheral bone marrow-derived cell
infiltration is not just evident in models of BBB compromise,
but can also occur in sub-inflammatory conditions as well.
Interestingly, increased infiltration of peripheral monocytes can
influence anxiety-like behavior, once again illustrating the ability
for immune signaling to influence higher-order CNS function
(Wohleb et al., 2014). This result, however, still needs more
investigation, as it is widely held that immune-cell infiltration is
a sign of neuroinflammation, and is not evident in sub-maximal
levels of central immune signaling.
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There is little direct evidence showing peripheral immune cell
migration in MDD due to the lack of a representative animal
model of MDD. Nevertheless, social defeat and psychological
stress can trigger increased trafficking of peripheral cell infiltra-
tion (Brevet et al., 2010; Wohleb et al., 2013). Given that MDD
is considered a stress disorder (for more information, see Section
“what does stress have to do with it?”), this indicates that periph-
eral cell infiltration could be involved inMDD. However, isolating
the exact cause of immune signaling in MDD is challenging,
and the extent of peripherally driven immune responses in MDD
patients is thus still unknown.
EFFECT OF INCREASED IMMUNE (TLR4) ACTIVITY ON CNS
NEUROTRANSMITTER ACTIVITY
So far, the best-characterized neuropathophysiology of MDD
within the CNS is the dysregulation in serotonin neurotransmis-
sion, but the exact cause of this alteration is still unclear. There
is growing evidence that glia are able to influence neurotrans-
mission, and through these mechanisms, glia can contribute to
the neuronal adaptations in MDD (Burke et al., 2014; Kreisel
et al., 2014). Through close appositions with synapses in tripar-
tite and tetrapartite arrangements, glia have access to the chemical
environment of the synapse. Functionally, astrocytes can con-
tribute to glutamate homeostasis by clearing excess glutamate
from synapses. During situations of increased neuroimmune sig-
naling, this process is impaired due to the down regulation of
astrocyte glutamate transporters (EAAT1 and EAAT2), causing
glutamate neurotoxicity and subsequent neuronal death (Tilleux
and Hermans, 2008; Persson et al., 2009; Fang et al., 2012).
In relation to MDD, glia express serotonin transporters
(Malynn et al., 2013), and can also directly inhibit serotonin
production during neuroinflammation through the production
of indoleamine-2,3-dioxygenase (IDO). IDO further interferes
with the synthesis of serotonin by catalyzing tryptophan, form-
ing quinolinic acid and 3-hydroxy-kynurenine, which can further
result in neurotoxicity (O’Connor et al., 2009). Through this
pathway, the increase in IDO reduces serotonin signaling as
seen in MDD by impairing serotonin production, and can also
cause direct damage to serotonergic neurons. Indeed, patients
with MDD display and increased circulating kynurenine to tryp-
tophan ratio, suggesting increased IDO activity (Quak et al.,
2014). Moreover, this effect is thought to mediate depressive
like behavior as a result of immune activation, as pharmacolog-
ical inhibition of IDO is able to attenuate the increase in cen-
tral immune signaling and depressive-like behavior in response
to LPS administration in rodant models (Corona et al., 2010;
Dobos et al., 2012). The ability of glia to influence serotoner-
gic neurotransmission illustrates that rather than replace ear-
lier notions of what causes depressive symptoms—that is, an
impairment in serotonin metabolism—neuroimmune mecha-
nisms instead contribute to and supplement neural mechanisms
of disease.
EFFECT OF MDD TREATMENTS ON IMMUNE SIGNALING
The immune to brain communication is not uni-directional,
since neuronal functions can also influence the activity of the
immune system. This is especially evident in current treatments
of MDD using SSRIs or SNRIs that work via alterations to
serotonin and noradrenaline, respectively. Anti-depressants have
shown to reduce LPS induced peripheral IL-6 and TNF-α pro-
duction (Manikowska et al., 2014). SSRI administration can
also attenuate CRH, TNF-α, and IL-1β mRNA expression in
the hypothalamus after chronic treatments (Alboni et al., 2013).
Glia are responsive to anti-depressant treatments, since SSRIs
can decrease gliotransmission (Dhami et al., 2013), and can par-
tially attenuate microglial secretion of TNF-α in response to
LPS. Pharmacologically blocking the reuptake of serotonin can
also reduce microglial reactivity and inhibit LPS-induced changes
in microglia morphology (Horikawa et al., 2010; Obuchowicz
et al., 2014). In addition, there is also evidence that antide-
pressants are protective against microglial- (Zhang et al., 2012)
and MPTP-induced neurotoxicity (Chung et al., 2011). Thus,
alterations to serotonergic neurotransmission can also influence
glial and central immune activity, and this may contribute to
the anti-depressive effects of SSRI. Together with evidence of
immune modulation of neurotransmission, this illustrates the
bi-directional communication between the neural and immune
systems in both normal and pathophysiology.
WHAT DOES STRESS HAVE TO DOWITH IT?
Stress refers to a challenge to the body’s homeostatic state,
and can be classified broadly as psychological, physiological
and immunological in origin. According to the diathesis-stress
model of depression, stress is essential to the development of
MDD, as stress is required in order to unmask the underlying
individual predisposition to the disorder (Monroe and Simons,
1991). Biological and environmental factors thus interact to
produce the physiological and psychological depression pheno-
type. Stress, regardless of type, activates the hypothalamus pitu-
itary and adrenal (HPA) axis, which forms the neuroendocrine
stress response. The HPA axis is therefore the most investi-
gated link between stress and MDD. Furthermore, TLR4 activa-
tion is considered an immunological stress, and recent research
demonstrates that it is deeply intertwined with the neuroen-
docrine stress response. Given the innate immune component
of MDD as outlined earlier, we propose that the role of TLR4
in MDD is mediated at least in part by its interaction with the
HPA axis.
THE CLASSICAL HPA AXIS
When activated, the HPA axis works to restore homeostasis fol-
lowing different stressors (Chrousos, 2009). Activation of the
HPA axis begins with neurons in the paraventricular nucleus
of the hypothalamus (PVN), which secrete corticotropin releas-
ing hormone (CRH). CRH then stimulates the pituitary gland
to release adrenocorticotropic hormone (ACTH) into the blood
circulation. Upon binding to melanocortin 2 receptor (MC2R)
expressed on the zona fasciculata layer of the adrenal cortex,
ACTH stimulates glucocorticoid (GC) production de novo. GC
binds to cytoplasmic glucocorticoid receptors (GR) and miner-
alocorticoid receptors (MR) at a higher affinity (Sapolsky et al.,
2000). Due to this higher affinity, the actions of baseline GC
are thus associated with MR binding, whereas GR actions are
attributed to upregulated GC by stressors.
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GR binding causes receptor translocation into the nucleus
through the aid of chaperone proteins such as heat shock pro-
tein 70 and 90 (HSP70, HSP90, respectively), where it can either
dimerise and bind to glucocorticoid response elements (GRE) on
DNA to either increase transcription of glucocorticoid responsive
genes, or interact with other proteins such as transcription factors
NF-κB and AP-1 (see Silverman and Sternberg, 2012 for review).
GC actions are therefore extremely complex. Furthermore, most
cells express GR, and thus GCs can influence the functions of
multiple systems through diverse endocrine actions. GCs are also
able to cross the BBB to influence CNS function including feed-
ing back upon its own secretion by signaling via GR in the
hippocampus to increase GABAergic tone on the PVN.
HPA ACTIVITY ALTERATIONS IN MDD
The HPA response is markedly changed during depression.
Specifically, patients with MDD exhibit heightened cortisol lev-
els in the morning, and possess a flatter diurnal slope throughout
the day (Dinan, 1994; Jarcho et al., 2013). This indicates that a
dysregulation in HPA activity is involved in the pathophysiology
of depression, and further raises important questions as to what
causes this HPA dysregulation, as well as how this fits in with the
immune adaptations outlined earlier.
The hypersecretion of cortisol could mean either a problem
with the feed-forward secretory pathway, or the negative feedback
loop within the HPA axis. The former is unlikely true, as adrenal
responsiveness to ACTH is normal in patients with depression
(Rubin et al., 2006), showing that adrenal function itself is
not altered in depressive disorders. On the other hand, patients
exhibit lower responsiveness to the dexamethasone suppression
test (DST), which tests GR mediated negative feedback onto HPA
activity (Holsboer-Trachsler et al., 1991). Dexamethasone was
also found to be less effective in suppressing immune activity
in patients with depressive disorders (Maes et al., 1994). Taken
together, GR function is modified in MDD, and patients develop
what is termed GC resistance. Given that the actions of GR influ-
ence multiple systems in the body, GC resistance could serve as a
link betweenMDD and immune dysregulation (Quan et al., 2003;
Silverman and Sternberg, 2012).
HPA hyperactivity may be sufficient to cause depressive
moods, since patients with Cushing’s syndrome, characterized
by hypersecretion of cortisol, often exhibit depressive symp-
toms (Starkman et al., 1981). In rodent models, administration
of corticosterone can also elicit depressive-like behavior, and
this effect is blocked by spironolactone, an MR antagonist (Wu
et al., 2013). Since MR is associated with baseline GC actions,
the increased secretion of cortisol in MDD patients may be in
part mediating the disorder via MR activation. HPA dysregu-
lation indeed presents itself to be integral to depressive symp-
toms. However, blocking GC signaling is not feasible due to
its widespread effects on cardiovascular, reproductive, metabolic
and immune function. Thus, recent attention has been turned
toward specific upstream modulators of HPA activity in stress
and MDD. Out of these investigations, the immune compo-
nent appears to be the most likely target due to the overlaps
between immune activation, the monoamine system, and the
HPA axis.
ACUTE TLR4 ACTIVATION TRIGGERS THE HPA AXIS
HPA activity is thought to mediate the immune involvement in
MDD. Using LPS, previous research has been able to show that
TLR4 signaling is able to stimulate the HPA axis (Mohn et al.,
2011). Further studies showed that TLR4 activation is sufficient to
cause GC release from adrenal cells (Vakharia and Hinson, 2004;
Kanczkowski et al., 2013). TLR4 activation can also cause CRH
gene upregulation in paraventricular neurons in the hypothala-
mus (Loum-Ribot et al., 2006), as well as increased CRH in serum
(Goebel et al., 2011). Pituitary cells stimulated by LPS also pro-
duce ACTH, but there is contrasting data on whether this effect is
CRH dependent (Elenkov et al., 1992; Mehet et al., 2012).
Despite clear evidence that innate immune activation via TLR4
can strongly stimulate the HPA axis, the exact mechanism is still
unclear, as it is not known if TLR4 can directly modulate neu-
ronal activity, or cause steroidogenesis via intracellular signaling.
Part of the problem is, as illustrated earlier, where in the system
LPS has the most effect, since it appears that TLR4 is present and
can trigger increased secretion of CRH, ACTH, andGC. The other
part of the problem lies in the many levels of immune activation
that can also influence neuroendocrine activity. The following
section reviews how TLR4 signaling can trigger the HPA axis and
it’s implications for MDD.
Cytokines and HPA activity
Cytokines are secreted by immune competent cells as a result of
innate immune stimulation, including TLR4 activation by various
ligands. As previously stated, cytokine administration is suffi-
cient to cause sickness behavior. Cytokines can also upregulate
HPA axis signaling on multiple levels through two main ways: (1)
through reducing negative feedback on HPA signaling, and (2) by
directly stimulating HPA activation. IL-1β, IL-6, and TNF-α are
able to reduce the efficacy of GR, thus disinhibiting GR induced
negative feedback onHPA activity (Pace et al., 2007; Bogaert et al.,
2010). This effect could be due to protein-protein interactions
with GR, which enables pro-inflammatory cytokines to influence
GR translocation, ligand binding affinity and GR binding to GRE
within the nucleus (for review, see Pace and Miller, 2009).
Secondly, cytokines can amplify the feed-forward signaling
within the HPA axis. IL-6 has been shown to potentiate CRH
activation of ACTH (Mehet et al., 2012), while IL-1β and stress
have an additive effect on CRH secretion from the PVN (Chover-
Gonzalez et al., 1993). Interestingly, peripheral and central IL-1β
is upregulated in response to acute stress within 1 h, and 3 h
after stress onset, respectively, and could therefore endogenously
prime the HPA response. Moreover, this study also found that the
administration of an IL-1β receptor antagonist diminished ACTH
responses to restraint stress (Ga˛dek-Michalska et al., 2011), show-
ing that cytokines may partially mediate stress induced HPA acti-
vation. Given that an increase in peripheral IL-1β and circulating
cortisol is observed in patients with MDD (Maes et al., 1991), this
permissive effect on ACTH secretion could be in part driving the
dysregulation between the immune and HPA secretion in MDD.
TLR4-related COX-2 production as part of steriodogenesis pathway
Besides cytokine interactions, COX-2 has also been shown to
mediate TLR4 involvement in modulation of HPA activity.
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COX-2, an enzyme upregulated by TLR4 activation, catalyzes
arachidonic acid into prostaglandin E2, which is part of the
steroidogenesis pathway. COX-2 is therefore involved in the syn-
thesis of GC at the level of the adrenal, and is shown to medi-
ate LPS induced steroidogenesis within adrenal cells (Vakharia
and Hinson, 2004). Furthermore, pharmacologically blocking
COX-2 systemically is able to inhibit restraint stress induced
GC both in vivo (Mouihate et al., 2010; Ma et al., 2013), and
in vitro (Martinez Calejman et al., 2011). The effects of COX-2
extend beyond the adrenal gland, as expression of COX-2 in
the PVN is important for sympathetic activation in response
to restraint stress (Yamaguchi et al., 2010). In addition, COX-2
inhibition can influence higher order functions, buffering the
effects of immobilization stress by reduced anxiety behavior and
improve locomotor functioning and learning (Kumari et al.,
2007).
Long-term effects of TLR4 activity on HPA axis function
Not only can TLR4 activation result in short-term stimulation
of the HPA axis, but TLR4 can also influence HPA activity long
after the stressor is resolved. For example, a single LPS chal-
lenge during early-life is sufficient to hyper-sensitize the CRH
and ACTH response to both subsequent LPS and restraint stress
when tested in adulthood, without baseline HPA differences when
compared to vehicle controls in a rodent model (Mouihate et al.,
2010). Early-life TLR4 activation also results in an increase in
anxiety behavior during adulthood (Sominsky et al., 2013), thus
fundamentally changing the stress response system. This sug-
gests that TLR4 activity during developmentally sensitive periods
may shape the HPA system, priming the system toward hyper-
reactivity, and may even be changing individual predisposition
toward stress-related disorders.
A good way of investigating the developmental consequence
of TLR4 is through the use of genetic knockout models. TLR4
knockout mice are observed to have different HPA pheno-
types when compared to match wild-type C57Bl/6 counterparts,
showing increased adrenal gland volume and correspondingly
higher baseline circulating glucocorticoid levels (Zacharowski
et al., 2006). The direction of this change is not univer-
sally found however, as preliminary findings from our labora-
tory in Balb/c background TLR4 knockout mice have yielded
opposite results. We have found that TLR4 genetic knockout
mice have smaller adrenal glands as well as lower circulat-
ing GC (unpublished). Additionally, circulating ACTH was also
elevated in mice lacking TLR4 when compared to matched
controls.
Despite the differences in adrenal size and baseline ACTH lev-
els, we found no difference between wild type and TLR4 knockout
mice, in terms of adrenal responsiveness to ACTH administration
in the same study (unpublished). Our findings support obser-
vations that systemic rather than adrenal MyD88 expression is
important in regulating HPA activity (Kanczkowski et al., 2013).
Taken together, these results suggest that although the TLR4 path-
way can influence HPA activity, the innate immune system has
little direct impact on adrenal function, and the observed HPA
differences are likely to be driven by mechanisms within the CNS
instead.
STRESS AND SYSTEMIC IMMUNITY
It is becoming clear that mood disorders such as depression have
both immune and neuroendocrine components. Through inter-
actions with the neuroendocrine system and central immune sig-
naling, TLR4 is central to the physiological responses to immune
stressors as well as baseline HPA activity. Yet at the same time, GCs
classically suppress the immune system including the TLR4 path-
way. When GCs bind to GR, immune suppression can occur in
twomain ways. Firstly, GR can directly interact with transcription
factors NF-κB and AP-1 through protein-protein interactions,
and in the process interfere with the pro-inflammatory transcrip-
tion (Ratman et al., 2013). Following nuclear translocation, GR
can also dimerise and bind to GRE on DNA, upregulating tran-
scription of anti-inflammatory or repressing inflammatory genes
such as IL-6 receptor gene (Muzikar et al., 2009). Both mech-
anisms appear important in driving anti-inflammatory actions
of GCs as DNA binding appears important for the resolution of
high-dose LPS induced inflammatory and behavioral response
(Silverman et al., 2013), while GR can interfere with NF-κB
induced transcription of proinflammatory genes (Novac et al.,
2006). GR not only functions on the intracellular level, but can
also downregulate macrophage expression of TLR4 mRNA in
a dose and time dependent manner (Du et al., 2012). Given
the varied roles of glucocorticoids in immune suppression, how
does stress, which strongly triggers the HPA axis, cause increased
immune signaling seen in MDD?
The answer likely lies in stress-induced adaptations, as recent
evidence in rodent models has shown that stress itself can be both
pro- and anti-inflammatory. Chronic footshock stress can induce
bone-marrow derived monocytes infiltration into the hippocam-
pus, thus increasing immune activity (Brevet et al., 2010). Acutely,
footshock stress can also result in concurrent neuroendocrine
and immune activation, characterized by increased hypothalamic
IL-1β and TNF-α, adrenal IL-6, and COX-2, in addition to cir-
culating ACTH and GC increase (Hueston and Deak, 2014). The
authors also showed that injection of ACTH and CRH induced
adrenal IL-6 and COX-2 mRNA expression, indicating that HPA
activation can be pro-inflammatory. The increase in immune
signaling seen in MDDmay therefore be driven by stress itself.
The elevation of neurokine signaling appears stressor spe-
cific. Illustrating this, a meta-analysis showed that stress-induced
IL-1β in the hypothalamus is most reproducible in footshock
and immobilization stress models (Deak et al., 2005). On the
other hand, social defeat stress increases prefrontal cortex IL-
1β, IL-6, and TNF-α expression (Audet et al., 2011), in addition
to increased monocyte infiltration (Wohleb et al., 2014). These
variations in regional cytokine levels thus indicate a complex rela-
tionship between stressor type and the innate immune system
within the CNS.
To reconcile the biphasic actions of HPA activation, in a
recent review, Frank et al. (2013) argued that the timing of
immune challenges and measurements is important in determin-
ing the direction of glucocorticoid actions. The authors proposed
that glucocorticoids are anti- inflammatory during the stres-
sor, but sensitizes the immune response after the stressor has
ended, during what the “recovery phase” following the resolu-
tion of the stressor (Frank et al., 2013). Thus, timing of the
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“second-hit” as well as measurements of immune functioning fol-
lowing both stressors is therefore imperative to measuring GC
actions on immune function. At this point, it is still unclear
what mechanisms drive this biphasic effect, and how long this
pro-inflammatory state persists following stress. In the following
section, we review potential mechanisms, as well as present the
case for TLR4 involvement in mediating the pro-inflammatory
actions of the HPA system.
MECHANISMS OF GLUCOCORTICOID INDUCED
PRO-INFLAMMATORY RESPONSES
DIRECT MECHANISMS THROUGH HPA ACTIVATION
The HPA axis can directly influence immune signaling in two
main ways, by reducing the inhibitory effects of glucocorticoid
actions, or by directly stimulating the immune system. As men-
tioned in the previous section, there appears to be some form of
GR adaptation, thus disrupting the actions of GR on the immune
system and negative feedback onto the HPA system. This effect
termed glucocorticoid resistance. Glucocorticoid resistance is pre-
dominantly thought to be due to either a reduced GR expression,
or a selective reduction in GRα and a corresponding upregula-
tion of GRβ, the inactive splice variant of the receptor that is
unable to bind glucocorticoids (Silverman and Sternberg, 2012).
Increased expression of pro-inflammatory cytokines correspond
to elevated expression of GRβ, which could drive the disinhibi-
tion to immune response (Carvalho et al., 2014). Glucocorticoid
resistance not only reduces glucocorticoidmediated immune sup-
pression, but can in itself increase NF-κB responses in PBMC
when exposed to glucocorticoids, thus reshaping the response to
a previously anti-inflammatory stimulus (Dawson et al., 2012).
Contrary to classical actions, HPA activation can also directly
trigger the immune response. CRH, which is secreted by PVN
cells, may also directly stimulate the innate immune system.
When exposed to CRH, mast cells have been shown to undergo
degranulation, releasing cytokines into the extracellular space
(Theoharides et al., 1995; Alysandratos et al., 2012). This directly
implicates CRH in the increased central immune or neurokine
signaling in stress-related disorders (Aguirre et al., 2013). On the
other hand, CRH can also induce microglial apoptosis in the
nanomolar range (Ock et al., 2006). It is therefore still unclear
how the pro and anti-inflammatory effects are balanced in stress
induced CRH release.
Pharmacological inhibition of GR reduces VCAM and ICAM
expression in the microvasculature (Gregory et al., 2009), indi-
cating the GR specific actions on immune cell migration. Indeed,
low doses can be pro-inflammatory by stimulating phagocytosis
and chemotaxis of macrophages via a GR mediated mechanism
(Zhong et al., 2013). It has been previously established that GCs
not only suppress the immune system, but at low doses directly
induces production of macrophage migration inhibitory fac-
tor (MIF), a pro-inflammatory cytokine (Calandra et al., 1995).
MIF can function as a chemokine, and stimulate CCL2 produc-
tion when administered to the microvasculature, thus promoting
migration of inflammatory cells to the site of damage (Gregory
et al., 2009). Physiologically, MIF is involved in wound healing
through promoting migration of endothelial progenitor cells to
wounds (Grieb et al., 2012). Conversely, MIF is also implicated
in the development of neuropathic pain (Alexander et al., 2012;
Lerch et al., 2014). The exact reason for immune activation fol-
lowing the HPA response is still debated, but one of the more
accepted reasons for this effect is that by increasing immune sig-
naling, MIF constrains the HPA response in order to counteract
glucocorticoid induced immune cell apoptosis. Through these
mechanisms, it is thus possible for heightened HPA activity and
immune activation to co-exist in patients with MDD.
TLR4 MEDIATED MECHANISMS OF STRESS-INDUCED
PRO-INFLAMMATORY RESPONSE
TLR4 mediates immune priming effects of stress
Given the often-contradictory results on HPA function, the com-
plexity of glucocorticoid signaling is becoming more appreci-
ated. In order to explain the complex actions of glucocorticoids
Sapolsky et al. (2000) proposed 4 categories of glucocorticoid
action - permissive, inhibitory, excitatory and priming, encapsu-
lating the different receptors activated, timing of response relative
to stressors and type of tissue activated. Illustrating this, gluco-
corticoids are excitatory in terms of heart function but inhibit
vascular function, cause the release of glucose aiding energy
expenditure, yet also trigger stockpiling of fat in adipose tissue.
At the same time, basal glucocorticoid expression can be per-
missive toward sympathetic activation of the adrenal medulla,
thus influencing stress responses even before the HPA activation
even occurs. Thus, glucocorticoids have different dose and time
response relationships across different tissues, and their actions
are dependent on basal or activated HPA states.
Recent studies are beginning to classify the priming or sen-
sitizing effect of stress and HPA activity on immune function.
Chronic variable and acute social disruptive stress can sensi-
tize HPA and immune response to subsequent LPS challenge,
differentially inducing larger neurokine and peripheral cytokine
responses (Gibb et al., 2013). Repeated social defeat stress can
also prime immune signaling in peripheral monocytes and den-
dritic cells in response to LPS, coupled with glucocorticoid resis-
tance during the first 48 h after stressor, measured by immune
cell expression following GC administration in vitro (Powell
et al., 2009). Importantly, this immune priming is also seen in
microglial populations 24 h after glucocorticoid treatment (Frank
et al., 2011). Moreover, GC administration in vivo has been con-
firmed to emulate stress induced immune sensitization (Frank
et al., 2010; Dey et al., 2014). This sensitizing effect was further
blocked by a GR antagonist, indicating that GR signaling is essen-
tial (Frank et al., 2012). TLR2 and TLR4 activity could also be
integral to glucocorticoid-induced immune priming in microglia,
as administration of their respective antagonists prior to tailshock
stress can prevent increased sensitivity in hippocampal tissues
collected 24 h after the end of the stressor (Weber et al., 2013).
Taken together, there appears to be crosstalk between the GR and
TLR4 pathways, and both receptors appear to be important in
driving immune cell sensitization and increased central immune
signaling following stress.
The immune-priming effect of stress is proposed to mediate
stress-induced side effects such as allodynia (Loram et al., 2011),
and drug abuse (Frank et al., 2011), and could potentially be
involved in MDD as well. PBMCs isolated from patients admitted
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for severe depressive episodes are more responsive to interferon-γ
(IFN-γ) stimulation (Schlaak et al., 2012). Along with increased
TLR4 mRNA and expression on PBMCs of patients with MDD
(Kéri et al., 2014), the increased immune signaling in MDD
patients could be indicative of a primed immune system, rather
than chronic inflammation.
DAMPs released during stress cause TLR4 activation
DAMPs, or alarmins, are released endogenously from stressed,
dead and dying cells as a signal for danger. They include HMGB1,
various HSP, ATP, and Uric acid. During normal physiological
activation, DAMPS have a non-inflammatory function within
the cell. Conversely during situations of tissue damage, when
released into the extracellular space, DAMPs alert the immune
system to the damage in order to promote repair and direct traf-
fic toward the damaged tissue, thus triggering the inflammatory
response. This inflammatory response is in part driven by TLR4,
since DAMPs including HMGB1 and various HSPs can activate
the TLR4 pathway (Hutchinson et al., 2009; Laird et al., 2014).
Furthermore, ATP can trigger innate immune signaling by acti-
vating a protein complex known as the inflammasome, which
induces the maturation and release of cytokines IL-1β and IL-18
via a caspase-1 dependent mechanism (Chen et al., 2013). This
effect is known to augment the inflammatory response to LPS,
therefore amplifying TLR4 signaling (Ghonime et al., 2014).
DAMPS including HMGB1, uric acid and HSP72 are also
released following tail-shock stress (Faraco et al., 2007; Maslanik
et al., 2013), and thus are not limited to situations of tissue
damage or cell death. DAMPs could therefore mediate the effect
of stress on triggering or sensitizing the immune response, and
this increased immune signaling may have wider implications for
MDD. It is notable, however, that the mechanisms regulating the
secretion of DAMPs in response to stress is not well characterized.
High mobility group box 1. HMGB1 functions as a chaperone
protein within the cell by binding to proteins and transporting
them between the cytoplasm and nucleus. During damage how-
ever, HMGB1 can be released into the extracellular space via an
inflammasome mediated mechanism (Lu et al., 2012). Neural tis-
sue is capable of releasing HMGB1 in response to glutamatergic
excitotoxicity and glial activation as a result of LPS adminis-
tration in vitro (Faraco et al., 2007). HMGB1 can also activate
central immune signaling, as it can trigger TLR4 similar to LPS,
via the MD2 and CD14 complex, and requires adaptor protein
MyD88 to trigger downstream inflammatory actions (Kim et al.,
2013). Moreover, psychological stress itself can induce an increase
in HMGB1. For example, thymocytes are responsive to 15min
restraint stress, and release HMGB1 via GR signaling (Billing
et al., 2012). There is further evidence showing that HMGB1
and GR can form complexes within the chromatin, increasing
the residence time of GR when bound to DNA (Agresti et al.,
2005). The functional consequence of this interaction, however,
is still unclear. Given that HMGB1 is responsive to stress, inter-
acts with GR, and is able to increase peripheral and central
immune signaling, stress-induced immune sensitization through
neurokine signaling could therefore be partially mediated by
HMGB1.
HMGB1 can also cause an upregulation of Matrix metal-
lopeptidase 9 (MMP9), an enzyme that results in the break-
down of the extracellular matrix (Qiu et al., 2010). Interestingly,
increased MMP9 in circulation is associated with mood disorders
such as depression and bipolar disorder (Domenici et al., 2010;
Rybakowski et al., 2013). Together with evidence that MMP9 can
also be upregulated as a consequence of microglial activity (Lively
and Schlichter, 2013), MMP9 could be a possible result of stress
induced HMGB1 upregulation and immune signaling within the
CNS in MDD.
Heat shock proteins.HSPs were first discovered in the drosophila
model to be produced in response to hyperthermia, and vary in
protein weights ranging up to 110 kDA. HSP regulate the fold-
ing and unfolding of other proteins, and are released in response
to cellular damage. Signaling danger, extracellular HSP can acti-
vate the innate immune system (Colaco et al., 2013). Within the
HSP family, HSP70 and HSP90, the 70 and 90 kDa variants, are of
most relevance to glucocorticoid and TLR4 signaling. HSP70 and
HSP90 can bind TLR4, resulting in release of pro-inflammatory
cytokines (Gong et al., 2009; Colaco et al., 2013). Furthermore,
HSP90 also serves as a chaperone protein for TLR4, trigger-
ing endocytosis in response to ligand binding (Triantafilou and
Triantafilou, 2004). Through these mechanisms, HSP90 plays an
integral role in TLR4 signaling and in TLR4 related neuropathic
pain (Hutchinson et al., 2009). Stress can also induce HSP expres-
sion, notably decreasing the ratio between GR and HSP70 and
HSP90 expression in the hypothalamus (Simic et al., 2012).
Interestingly, HSP90 is a well-characterized chaperone pro-
tein for GR nuclear translocation and permits GC binding to
GR (Ricketson et al., 2007). Although important for binding and
translocation, Increased HSP90 expression can also impair GR
function (Matysiak et al., 2008). This effect increases in chronic
stress as compared to acute models of stress, and thus is proposed
as one facet of glucocorticoid resistance. Stress induced changes in
HSP can therefore either directly activate TLR4, change the traf-
ficking TLR4 and GR, as well alter GR binding capacity. However,
to what extent each of these mechanisms is involved, and the
magnitude of the change has yet to be investigated in models
of depressive-like behavior. Nevertheless, given the involvement
in TLR4 and GR signaling, HSP could be an avenue for fur-
ther research in linking stress and increased immune signaling
in MDD.
TLR4 activation as a result of gut translocation of microbes
One way in which TLR4 ligands are upregulated by stress is
through intestinal translocation. Recently, the role of gut micro-
biota in potentiating differences in mood and behavior is gaining
traction within the literature (Hsiao et al., 2013). It has been
hypothesized that stress can cause a disruption in intestinal tight
junctions, which would increase translocation of microbiota into
the system, thus inducing inflammatory responses. Indeed, GR
appears to be involved in gut HSP70 upregulation and intestinal
permeability in response to restraint stress (Ait-Belgnaoui et al.,
2012, 2014).
There is some evidence showing that intestinal decontamina-
tion using orally administered antibiotics is able to block the tight
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junction disruption, as well as inflammatory and HPA responses
to psychological stress (Gárate et al., 2011). Furthermore, antibi-
otic treatment is shown to mirror the ability of TLR4 antagonist
in blocking stress induced depressive-like behavior (Gárate et al.,
2011). This hypothesis is thus showing promise for develop-
ing new medication targeting the gut-brain axis in regulating
behavior. On the other hand, the exact mechanisms of this gut-
brain communication in respect to stress and MDD are unclear,
since both ascending pathways and peripheral immune signaling
could potentially be involved. In addition, the extent of intesti-
nal translocation in the acute stress response requires more study,
since it is not known if this effect is stressor specific.
CONCLUSIONS
It is evident that the immune, neural and neuroendocrine sys-
tems are in constant multi-directional communication, and in
the case of stress and MDD, patients exhibit a dysregulation of
all three systems. Thus, the difficulty in finding treatment targets
lies in untangling the multi-layered relationships. In the current
review, we presented evidence centered on immune modulation
of CNS and stress-induced adaptations observed in models of
MDD. Stress is regarded as a necessary factor for the development
ofMDD through adaptations to the neuroendocrine and immune
responses.
Through use of knockout models as well as pharmacologi-
cal agonists and antagonists, TLR4 activation has been shown to
elicit depression-like symptoms in animal models both behav-
iorally and physiologically. Additionally, TLR4 could potentially
mediate stress-induced immune signaling both in the periphery
and within the CNS, as well as underlie stress-induced immune
activity, through interactions with DAMPs, MAMPs, and GC
signaling (Figure 1). TLR4, an innate immune receptor, could
therefore be important in investigating the immune involvement
in the pathophysiology of MDD.
On the other hand, this direct relationship between TLR4
and depression is still not fully understood, although timing
and location of TLR4 activation appears to be important. The
mode in which TLR4 influences MDD is not established, even
though cytokines appear to be essential to the development of
sickness behavior, other mechanisms such as direct interaction
between TLR4 signaling pathway and other receptors (for exam-
ple, GR) or intracellular signaling molecules could also play a
role in the development of the disorder. Furthermore, due to the
many compounds that can trigger TLR4 activation, an obvious
question would be to identify which of those are most rele-
vant to MDD. Critically, there is a need to move away from
the use of LPS in the investigation of MDD, since it constrains
the generalizability of conclusions to infectious factors. Although
the immune system appears to be involved in the pathophys-
iology of MDD, it is unlikely that bacterial infections are the
main factor, especially given that cytokines themselves can induce
behavioral change in the absence of sickness. Instead, individual
differences in immune activity could originate from alterations
to immune signaling during critical periods during development,
genetic disposition, or epigenetic changes that contribute to pre-
dispositions (Bilbo and Schwarz, 2009). Moreover, due to the
FIGURE 1 | Stress and individual predisposition combine to cause
various immune, neuroendocrine, and neural adaptations observed in
MDD. Immune adaptations are at least in part attributed to TLR4-related
mechanisms, either through direct activation by ligands (DAMPs and
MAMPs) released as a result of stress, or by long-term impairment caused by
genetics and early-life experiences. GCs can also interact with
TLR4-dependent and GR-dependent mechanisms to induce systemic
changes. In patients with MDD, these adaptations are not isolated to their
respective systems, but instead further augment their deleterious effects
through tri-directional communications.
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sub-inflammatory and state driven nature of heightened immune
signaling in MDD, endogenous mechanisms including DAMPs,
neuroendocrine, neurogenic signals, or an increase in gut translo-
cation of microbiomes are more likely involved. Thus, in the
search for a more efficacious treatment of MDD, the impact on
neural, neuroendocrine and immune systems must be considered
within representative models of the disorder.
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